This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Exscientia acquires personalised medicine AI pioneer Allcyte

Exscientia acquires personalised medicine AI pioneer Allcyte

15 Jun 2021

Deep learning platform evaluates drug activity in patient tumour microenvironments with single cell resolution First AI platform clinically validated to improve treatment outcomes in prospective study Exscientia, a clinical stage pharmatech company, has entered into a binding agreement to acquire Allcyte, a leader in artificial intelligence (AI) based precision medicine.  The combination expands Exscientia’s translational capabilities... Read more

OBN Announce the 2020 OBN Award winners

OBN Announce the 2020 OBN Award winners

14 Jun 2021

We are delighted to announce the winners of the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London. The Awards, which are in their 12th year, shine a light on companies at all stages of development, recognising inspirational leadership, exciting innovation, novel and exciting approaches to unmet clinical need, outstanding company progression and the delivery of real-life... Read more

Cytox welcomes FDA’s approval of Biogen’s Aduhelm (aducanumab) to treat Alzheimer’s disease

Cytox welcomes FDA’s approval of Biogen’s Aduhelm (aducanumab) to treat Alzheimer’s disease

08 Jun 2021

Cytox welcomes FDA’s approval of Biogen’s Aduhelm (aducanumab) to treat Alzheimer’s disease Cytox genoSCORE-LAB test can identify patients most at risk of cognitive decline, and potentially most likely to benefit from new drug 8th June 2021: Oxford and Manchester, UK. Cytox Ltd, which provides non-invasive, risk assessment and patient stratification tools for Alzheimer’s disease (AD) and dementia, welcomes the decision from the US FDA... Read more

Oxular appoints Dr. Friedrich Asmus as CMO

Oxular appoints Dr. Friedrich Asmus as CMO

07 Jun 2021

Dr. Asmus brings two decades of experience leading global clinical and translational research programs for both retinal and rare diseases. OXFORD, UK, 7 June 2021 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces it has appointed Dr. Friedrich (Fritz) Asmus as Chief Medical Officer. Dr. Asmus will lead all medical, clinical, and regulatory functions to... Read more

MoA Technology moves to The Oxford Science Park

MoA Technology moves to The Oxford Science Park

21 May 2021

MoA Technology has moved to the Bellhouse Building, a prestigious new facility recently opened at The Oxford Science Park. The first of more than 100 Oxford Sciences Innovation companies focused on cutting-edge technologies re-located to the Science Park in 2018.  More than 3,500 people work there across areas including immunology, artificial intelligence and systems biology. The Bellhouse Building is the most recently completed of three... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More